Gregston Nelson, MD
Family Medicine · Omaha, NENPI 1750476925
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Pfizer at 30.5% of the total. Reporting peaked in 2023 at $659 and has fallen 81.6% since, to $121 in 2025.
Across 159 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$825
- Novo Nordisk$300
- Lilly USA, LLC$235
- AstraZeneca$205
- Amgen$120
- AbbVie$118
- plus $899 from 27 others
Across 10 payments — averaging $14,472 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$130K
- Novo Nordisk AS$13K
- Amgen$2K
What the payments were for
- Travel & lodging$1214%
- Food & beverage$2,54894%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 62 | $825 |
| Novo Nordisk | 18 | $300 |
| Lilly USA, LLC | 14 | $235 |
| AstraZeneca | 8 | $205 |
| Amgen | 7 | $120 |
| AbbVie | 6 | $118 |
| Nestle Healthcare Nutrition Inc. | 3 | $88 |
| Grifols USA, LLC | 4 | $88 |
| Procept Biorobotics Corporation | 1 | $60 |
| Medtronic | 2 | $57 |
| Boehringer Ingelheim | 3 | $53 |
| GSK | 3 | $52 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Abbott | 2 | $36 |
| Bayer | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Exact Sciences | 2 | $30 |
| Seqirus USA Inc | 1 | $29 |
| VBI Vaccine (delaware) Inc. | 2 | $29 |
| Electromed, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $24 |
| Sanofi | 1 | $21 |
| Boston Scientific | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
How this compares
$2,701 in reported general payments places this provider in the 80th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 801 | $247,267 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 769 | $164,620 |
| EliquisApixaban | 58 | $57,162 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 134 | $41,075 |
| XareltoRivaroxaban | 20 | $20,918 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 313 | $20,619 |
| JanuviaSitagliptin Phosphate | 14 | $8,838 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,931 |
| Metoprolol Succinate | 156 | $2,037 |
| Simvastatin | 222 | $1,797 |
| Amlodipine Besylate | 282 | $1,734 |
| Omeprazole | 120 | $1,615 |
| Levothyroxine Sodium | 139 | $1,610 |
| Atorvastatin Calcium | 198 | $1,573 |
| Olmesartan Medoxomil | 116 | $1,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerAbrysvo, Eliquis | $825 | $304,429859 claims |
| GSKShingrix, Arexvy | $52 | $205,695903 claims |
| Johnson & JohnsonXarelto | $11 | $20,91820 claims |
| MerckJanuvia | $17 | $8,83814 claims |
| AstraZenecaSymbicort | $205 | $3,93111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Omaha
- Gerard StanleyOmaha$50K
- Yongge LiuOmaha$15K
- M DadaOmaha$14K
- Christopher ConnollyOmaha$12K
- Paul VanaOmaha$12K
- Stephen TetraultOmaha$11K
- James RamigOmaha$11K
- Jeffrey RappOmaha$10K
- Christine Carlson RahnOmaha$10K
- Joseph DumbaOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.